Human Molecular Genetics Advance Access published online on September 13, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi342
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 INSERM U656 and Centre Français des Porphyries, Université Paris VII, Hôpital Louis Mourier, 92701 Colombes, France; Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Ambroise Paré, Faculté de Médecine Paris - Ile de France Ouest, 92100 Boulogne-Billancourt, France
* To whom correspondence should be addressed. Hereditary coproporphyria (HCP), an autosomal dominant acute hepatic porphyria, results from mutations in the gene that encodes coproporphyrinogen III oxidase (CPO). HCP (heterozygous or rarely homozygous) patients present with an acute neurovisceral crisis, sometimes associated with skin lesions. Four patients (two families) have been reported with a clinically distinct variant form of HCP. In such patients the presence of a specific mutation (K404E) on both alleles or associated with a null allele, produces a unifying syndrome in which hematological disorders predominate: "harderoporphyria". Here, we report the fifth case (from a third family) with harderoporphyria. Additionally, we show that harderoporphyric patients exhibit iron overload secondary to dyserythropoiesis. To investigate the molecular basis of this peculiar phenotype, we first studied the secondary structure of the human CPO by a predictive method, the hydrophobic cluster analysis (HCA) which allowed us to focus on a region of the enzyme. We then expressed mutant enzymes for each aminoacid of the region of interest, as well as all missense mutations reported so far in HCP patients and evaluated the amount of harderoporphyrin in each mutant. Our results strongly suggest that only a few missense mutations, restricted to five aminoacids encoded by exon 6, may accumulate significant amounts of harderoporphyrin: D400-K404. Moreover, all other type of mutations or missense mutations mapped elsewhere throughout the CPO gene, lead to coproporphyrin accumulation and subsequently typical HCP. Our findings, reinforced by recent crystallographic results of yeast CPO, shed new light on the genetic predisposition to HCP. It represents a first monogenic metabolic disorder where clinical expression of overt disease is dependent upon the location and type of mutation; resulting either in acute hepatic or erythropoietic porphyria.
Received July 4, 2005
Revised September 7, 2005
Accepted September 7, 2005
Article
Mutations in Human CPO gene predict clinical expression of either hepatic Hereditary Coproporphyria or erythropoietic Harderoporphyria
2 INSERM U656 and Centre Français des Porphyries, Université Paris VII, Hôpital Louis Mourier, 92701 Colombes, France
3 INSERM U656 and Centre Français des Porphyries, Université Paris VII, Hôpital Louis Mourier, 92701 Colombes, France; Department of pediatrics, Faculty of Medicine I, Charles University, Praha, Czech Republic
4 Laboratoire d'Ingénierie des Protéines et Contrôle Métabolique, Département de Biologie des Génomes, Institut Jacques Monod, CNRS UMR7592, Université Paris VI et VII, 75005 Paris, France
5 Service de Dermatologie, Cliniques Universitaires Saint-Luc, 1200 Bruxelles, Belgium
6 Service des Maladies du Sang, Hôpital Claude Huriez, 59037 Lille, France
7 Laboratoire de Biochimie et Génétique Moléculaire, Hôpital Ambroise Paré, Faculté de Médecine Paris - Ile de France Ouest, 92100 Boulogne-Billancourt, France
Jean-Charles Deybach, E-mail: jean-charles.deybach{at}lmr.ap-hop-paris.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?